SUR1 Receptor Interaction with Hesperidin and Linarin Predicts Possible Mechanisms of Action of Valeriana officinalis in Parkinson by Gesivaldo Santos et al.
ORIGINAL RESEARCH
published: 02 May 2016
doi: 10.3389/fnagi.2016.00097
SUR1 Receptor Interaction with
Hesperidin and Linarin Predicts
Possible Mechanisms of Action
of Valeriana officinalis in Parkinson
Gesivaldo Santos 1*, Lisandro Diego Giraldez-Alvarez 2, Marco Ávila-Rodriguez 3,
Francisco Capani 4, Eduardo Galembeck 5, Aristóteles Gôes Neto 6, George E. Barreto 3,7,8*
and Bruno Andrade 1
1 Departamento de Ciências Biológicas, Universidade Estadual do Sudoeste da Bahia, Jequié, Brazil, 2 Programa Nacional de
Pós-Doutorado (PNPD-CAPES), Departamento de Química e Exatas, Universidade Estadual do Sudoeste da Bahia, Jequié,
Brazil, 3 Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, DC,
Colombia, 4 Instituto de Investigaciones Cardiológicas “Prof. Dr. Alberto C. Taquini” (ININCA), UBA-CONICET, Buenos Aires,
Argentina, 5 Departamento de Bioquímica, Instituto de Biologia, Universidade Estadual de Campinas—UNICAMP, Campinas,
São Paulo, Brazil, 6 Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Feira de Santana,
Brazil, 7 Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile, 8 Universidad Científica del Sur,
Lima, Peru
Edited by:
Gemma Casadesus,
Kent State University, USA
Reviewed by:
Junming Wang,
University of Mississippi Medical
Center, USA
Andres Mauricio Pinzón,
Universidad Nacional, Colombia
*Correspondence:
Gesivaldo Santos
colisor@gmail.com;
George E. Barreto
gsampaio@javeriana.edu.co
Received: 20 August 2015
Accepted: 18 April 2016
Published: 02 May 2016
Citation:
Santos G, Giraldez-Alvarez LD,
Ávila-Rodriguez M, Capani F,
Galembeck E, Neto AG, Barreto GE
and Andrade B (2016) SUR1
Receptor Interaction with Hesperidin
and Linarin Predicts Possible
Mechanisms of Action of Valeriana
officinalis in Parkinson.
Front. Aging Neurosci. 8:97.
doi: 10.3389/fnagi.2016.00097
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. A
theoretical approach of our previous experiments reporting the cytoprotective effects
of the Valeriana officinalis compounds extract for PD is suggested. In addiction to
considering the PD as a result of mitochondrial metabolic imbalance and oxidative
stress, such as in our previous in vitro model of rotenone, in the present manuscript
we added a genomic approach to evaluate the possible underlying mechanisms of
the effect of the plant extract. Microarray of substantia nigra (SN) genome obtained
from Allen Brain Institute was analyzed using gene set enrichment analysis to build a
network of hub genes implicated in PD. Proteins transcribed from hub genes and their
ligands selected by search ensemble approach algorithm were subjected to molecular
docking studies, as well as 20 ns Molecular Dynamics (MD) using a Molecular Mechanic
Poison/Boltzman Surface Area (MMPBSA) protocol. Our results bring a new approach
to Valeriana officinalis extract, and suggest that hesperidin, and probably linarin are able
to relieve effects of oxidative stress during ATP depletion due to its ability to binding
SUR1. In addition, the key role of valerenic acid and apigenin is possibly related to
prevent cortical hyperexcitation by inducing neuronal cells from SN to release GABA
on brain stem. Thus, under hyperexcitability, oxidative stress, asphyxia and/or ATP
depletion, Valeriana officinalis may trigger different mechanisms to provide neuronal cell
protection.
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INTRODUCTION
Parkinson’s Disease (PD) is the second most common
progressive neurodegenerative disorder affecting older American
adults and is predicted to increase in prevalence as the USA
population ages. A population-based study of US Medicare
beneficiaries found a mean prevalence of 1.6% for PD among
persons 65 years and above (Beitz, 2014). This disease is
characterized by a selective and progressive degeneration of
dopaminergic neurons and the presence of Lewy bodies in
the neurons of the Substantia Nigra pars compacta (SNpc;
Cabezas et al., 2012, 2014; dos Santos et al., 2014, 2015; Willard
et al., 2015). Imaging studies have shown that 70% of the
dopaminergic neuron loss from SN is the result of a scarcity
in the catecholamine neurotransmitter dopamine, generating
the characteristic motor symptoms of PD (Rieckmann et al.,
2015). The cause of dopaminergic cell death in PD remains
unknown, but it seems like to be associated with a number
of insults that may trigger programmed cell death such as
calcium influx, oxygen free radicals species of oxygen (ROS) and
mitochondrial complex I (Cx-I) inhibition (Hald and Lotharius,
2005; Abdin and Hamouda, 2008; Barreto et al., 2011; Cabezas
et al., 2012).
Therapeutic efforts aimed at the removal of ROS or
prevention of their formation may be beneficial in PD. In
this regard, natural products are attractive sources of chemical
structures that exhibit potent biological activities with desirable
pharmacological profiles. Several reports have suggested that
flavonoids and alkaloids may be useful to protect cells from
ROS toxicity (Cummings and Zhong, 2006; Albarracin et al.,
2012; Sutachan et al., 2012; Kwon et al., 2014; Bae et al., 2015;
Hiep et al., 2015). The presence of flavonoids in Valeriana
officinalis extract makes this plant attractive for the search
of a daily neuroprotective product for human consumption
(Adel Pilerood and Prakash, 2014). However, it is important
to consider that an extract is a mixture of different substances
and, thus, other compounds may be responsible for these effects.
Candidates that can act in CNS may also include alkaloids,
terpenes and phenolic compounds, volatile oils, like valerenic
acid or valeranone, or the valepotriate group (Houghton,
1999; Kennedy and Wightman, 2011). In Brazil, Valeriana
officinalis has been used in traditional medicine for its sedative,
anticonvulsant, hypnotic effects, and anxiolytic activity (Carlini,
2003).
Previously, our group (de Oliveria et al., 2009) observed
that Valeriana officinalis decreased rotenone-induced apoptosis
in human neuroblastoma SH-SY5Y cells in a PD in vitro
model. In spite of some hypothetical addressed designers
and anatomic limitations in this model, the real mechanism
involved in Valeriana officinalis-induced neuroprotection, not
only in vitro, but also in a true systemic neural network
on PD, remains to be completely delineated. The rotenone
model largely only gained attention following the seminal
article by the Greenamyre group, which demonstrated for
the first time that rotenone administered systemically to
rats can reproduce the hallmarks of PD (Betarbet et al.,
2000).
Rotenone, a flavone pesticide, inhibits Cx-I of the
mitochondrial electron transport chain leading to reduced
ATP production and electron leakage that can form reactive
oxygen species such as superoxide, subsequently causing
reduced glutathione levels and oxidative stress (Cabezas et al.,
2012; Johnson and Bobrovskaya, 2015). Some previous studies
have shown that Cx-I impairment may be inherited in familial
PD, indicating that Cx-I might account for some types of the
sporadic forms of the disease (Dawson and Dawson, 2003).
In this article, our aim was to provide some mechanistic
insights into the neuroprotective action of the Valerian’s
extract, taking into account the necessity of overcoming some
clinical and structural constraints raised in our previous
experimental model of PD in neuroblastome SH-SY5Y (de
Oliveria et al., 2009). To accomplish this, we are using a
powerful method of large-scale transcriptional profiling,
combined with system biology techniques and pathway
analysis to address the interactome of human SN, targeting
genes related with the PD. Legal, ethical questions and high
experimental costs make the computational system biology a
reliable alternative as a back-end or first approach screening
either before or after the laboratory bench (Edwards et al.,
2011).
MATERIALS AND METHODS
In our previous study, de Oliveria et al. (2009), argued that
the extract of Valeriana officinalis must be a target in the
search for new agents for the treatment of PD. In this study,
cell viability assays clearly showed that the aqueous extract of
Valeriana officinalis protected SH-SY5Y cells against damage
induced by rotenone, but the underlying mechanisms are
not fully understood. Indeed, it is not clear how Valeriana’s
extracts may act on human PD brain. To address this question
we have to deal with two different issues: e.g., (i) why
not all dopaminergic neurons fall in death in PD (Betarbet
et al., 2000); and (ii) which of the extract components take
part on this process. In spite of the structural constraint,
we have performed a mechanistic model targeting changes
in hub genes expression, assuming the PD as a result of
imbalance between ROS and ATP depletion in mitochondria
of neurons containing dopamine in SN (Yao and Wood,
2009).
Microarray data were retrieved from the Allen Brain Atlas1,
an online database containing valued assets freely available
of the entire genome of the human brain (Hawrylycz et al.,
2012). Data were obtained interactively during the experiment,
selecting the structures of interest from six subjects. The basal
ganglia SN was chosen in a list, as being the most remarkable
structure in PD. The array of genes obtained (Supplementary
Table 1) were used as seed input list for the two applications
Gene2Fan2 (Dannenfelser et al., 2012) and Expression2Kinase
(Chen et al., 2012) tuning to developing network biology protein-
protein interaction. To determine the high degree of connectivity
1www.brain-map.org/
2http://actin.pharm.mssm.edu/genes2FANs/
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FIGURE 1 | Hierarchical clustering used to get insight about gene hub from microarray list.
between genes or ‘‘hub genes’’, it was used the centrality
measurement (CM). CM is related to the value function of a
node in a graph representing a complex network. The index
can be derived from the number of directed paths arriving
or living the node. For better overview, see Opsahl et al.
(2010).
The next step was to access how the main components
of Valeriana could be acting in the modulation of pathways
associated with these transcripts on PD’s (Figure 1). In order
to achieve this, we compared the similarity between the list of
drugs obtained from X2Kinase (Chen et al., 2012) and Enricher3
(Chen et al., 2013), using the algorithm of similarity ensemble
approach4 (Keiser et al., 2007). Similarity Ensemble Approach
(SEA) makes use of the Tanimoto’s algorithm, a coefficient
based in a reliable mathematical model for computing molecular
similarities. Using this method, it is possible to generate a
molecular fingerprint, which can be used to compare a set
of multiple molecules at once in a reduced computing time.
Different chemical groups are used to generate the fingerprint
patterns (Bajusz et al., 2015).
The structure of each target molecule (transcripts of hub
genes) was obtained from PDB.5 All Valerian compounds
structures were obtained from PubChem database6 and
saved in sdf format. In addition, ligand structures were
3http://amp.pharm.mssm.edu/Enrichr/
4http://sea.bkslab.org/search/
5www.pdb.org
6http://pubchem.ncbi.nlm.nih.gov/
previously checked by Marvin 15.4.207 for docking studies.
Before docking calculations, we used Autodock Tools 1.5.6
(Trott and Olson, 2010) in order to prepare protein and
ligand structures according to the following steps: (1) define
a grid box for each protein target, considering each active
site previously described by crystallographic studies; (2)
check each ligand structures for torsions, as well as adding
polar hydrogens, Gaigster and Kollman charges; (3) save all
molecules in pdbqt format. Autodock Vina (Trott and Olson,
2010) was used to calculate affinity energies for each complex.
Discovery Studio 4.0 was used to generate 2D interaction
maps, considering a 2.0 Å distance between the ligand and
the active pocket amino acids. Molecular Dynamics (MD)
simulations were performed by GROMACS 5.0.58, using
Molecular Mechanic Poison/Boltzman Surface Area (MMPBSA)
protocol for 20 ns of simulation time. After each MD simulation
set, we generated Root Mean Square Deviation (RMSD)
graphics for both complexes and individual ligands, and for the
number of hydrogen bonds generated during the simulation
time.
RESULTS
We have reconstructed a gene map of microarray expression
from Allen Brain Atlas9, a public database maintained by
7https://www.chemaxon.com/
8http://www.gromacs.org/
9http://www.brain-map.org
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FIGURE 2 | Pathway association between TH and metabolic process via ABCC8 (Kir6.2) (A). The six hub genes obtained from Allen Brain Atlas via yEd
application (B).
Allen Brain Institute (Hawrylycz et al., 2012). In the first
step, 101 genes (Supplementary Table 1) were organized
in hierarchical clustering and used as seed input list of
the applications Expression2Kinases (Chen et al., 2012)
and Enricher10 to provide enrichment (GSEA; Chen
et al., 2013). A list of 98 genes obtained was analyzed
via yEd11 and optimized to genes associated to PD. Six
clusters emerged forming the sub networks alpha-synuclein
(SNCA), leucine-rich repeat kinase 2 (LRRK2), tyrosine
hydroxylase (TH), Casein kinase 1 (CNSK1), Prohibitin
2 (PHB2) and Bcl-2-associated death promoter (BAD)
(Figure 2A).
To assess genomic profile, the six hubs (Figure 2B) were
confronted using AmiGO12 (Ashburner et al., 2000) and
Enricher13 (Chen et al., 2013). As a result, all GO processes
previously generated were related to proteasome, and PD.
Data were confirmed from pathways resources such as Kegg14,
BioCarta15 and Reactome16 assessed directly from Enricher17
(Chen et al., 2013).
Even though the genome profile of SN has revealed six
major genes, the use of centrality measure reported the gene
SNCA as the highest degree. SNCA acts inhibiting TH directly,
10http://amp.pharm.mssm.edu/Enrichr/
11www.yworks.com
12http://amigo.geneontology.org/amigo
13http://amp.pharm.mssm.edu/Enrichr/
14http://www.genome.jp/kegg/
15http://www.biocarta.com
16http://www.reactome.org/
17http://amp.pharm.mssm.edu/Enrichr/
preventing dopamine release (Henchcliffe and Beal, 2008).
To gain insights into these mechanism of action, we needed
to filter out the genes, in these network, whose transcripts
could have a potential involvement with dopamine, rotenone,
mitochondrial metabolism, mitochondrial ROS imbalance and
the compounds of Valerian related with the previous experiment
of de Oliveria et al. (2009). But now, we have considered just
a new structural parameter associated to a cortical inhibition
by neuronal cells of SN. This process was achieved using
Pathwaycommons, whose purpose was to identify commons
pathways between hub genes.18 To perform molecular docking
analysis (Figure 3) of transcripts from the same network
linking SNCA and TH with the main compounds of the
plant, we used Autodock Vina Tools (Trott and Olson, 2010;
Table 1).
To identify a viable mechanism of action for the Valerian
extract, we selected apigenin, linarin, hesperidin and valerenic
acid as the main representative compounds of the four families of
substances present on the extract (National Toxicology Program,
Chemical Information Review Document, 2009). These elements
have been compared with drugs of recognized action on the
SNCA and TH, both transcripts of the hub genes SNCA and TH,
respectively (Table 2).
Ligand-Based Screening Approach
Drug targets were selected based on the profile of hub genes
SNCA and TH generated by the Enricher application (Keiser
et al., 2007). Furthermore, drugs were divided into cAMP
18http://www.pathwaycommons.org
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FIGURE 3 | Docking between alpha-synuclein (SNCA) and Valerian
compounds. Apigenin (green) and valerenic acid inside active site, while
linarin and hesperidin appears out.
TABLE 1 | Affinity energies for docking calculations between
alpha-synuclein and tyrosine hydroxylase with Valerian compounds.
Target Valerian RMSD Affinity energy
compound (Kcal/mol)
SNCA Apigenin 9.019 −5.1
Valerenic acid 9.548 −4.4
Valerenic acid 0 −7.4
TH Apigenin 0 −8.9
Linarin 0 −9.3
Hesperidin 0 −9.4
TABLE 2 | Similarity Ensemble Approach (SEA) search results for Valerian
compounds.
Known drug Valerian compound Max TC
Methylpredinisolone Acid valenenic 0.60
Norethynodrel Acid valenenic 0.59
Androsterone Acid valenenic 0.52
Menadione Apigenin 0.51
Atractyloside Hesperidin 0.47
Atractyloside Linarin 0.45
Resveratrol Apigenin 0.45
Menadione Linarin 0.42
up and down regulation (Table 2). The search tool SEA19
(Keiser et al., 2007), was used to retrieve the probable similarity
between drugs and the targets of Valerian, using the Tanimoto’s
Coefficient (Max TC; Keiser et al., 2009). According to Table 2,
19http://sea.bkslab.org
FIGURE 4 | Valerian compounds inside TH active site. In this docking,
apigenin (green), valerenic acid (yellow), hesperidin (cyan) and linarin (orange),
all the molecules interacting with TH active site.
FIGURE 5 | Kir receptor complexed with Valerian compounds. Apigenin
(cyan) and valerenic acid (green) interacting with active site. Hesperidin and
linarin did not fit in the binding site of Kir.
we observed that glucocorticoids are the major class of drug
widely related to gene profile obtained for the SN. In SEA
results, the main components of Valerian that shared structural
similarity with target drugs was valerenic acid (Max TC =
0.60) and apigenin (Max TC = 0.51). Both key compounds of
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plant extract, which are recognized on literature as aggregation
inhibitors of SNCA, as observed in Figure 3 (Uversky et al.,
2014).
Pathways and Molecular Docking
As observed in Figure 2A, obtained from the Pathwaycommons,
the gene encoding the protein kinase-A (PRKCA), associated
to several cell functions, such as apoptosis, emerges as a link
between the hub gene SNCA, TH and the main mitochondrial
genome expressed on SN cells.
It appears significant that ABCC and KCNJ families
emerge as a high connectivity node in this new subnetwork,
since they are tied to metabolic control with the membrane
potential of mitochondria (Akao et al., 2001; Deutch and
Winder, 2006; Wang et al., 2011). Therefore, molecular
docking was used to evaluate and quantify the interaction
of Valerian compounds with TH, K+ inward rectifier
channel (ABCC8) and sulfonylurea receptor (KCNJ11;
Figures 4–6). According to the literature, GABAergic
neuronal cells of Substantia Nigra pars compacta (SNpc),
a remarkable area in PD, exhibit a large expression of
ABCC8 to control GABA release on brain stem. In this
way, we decided to dock GABAA receptor with components
of valerian to predict whether the extract could act as a
modulator of cortical excitability, feature not tested in de
Oliveria et al. (2009), but capable of being evaluated in
a in silico model hereafter. Dynamic simulations retrieve
energy values for docking calculations between GABAA
(2YOE), the target and the four Valerian compounds (ligands;
Figures 7A–F).
FIGURE 6 | Apigenin (cyan), valerenic acid (green), hesperidin (yellow)
and linarin (orange) complexed with SUR1.
Valerian Compounds and GABA
As observed in Figures 7A–F, only valerenic acid and apigenin
remain in the binding pocket after a set of 20 ns MD simulation.
In order to validate the GABAergic effect of valerenic acid
and apigenin with GABAA receptor (2YOE), we re-dock the
crystallographic structure of Flurazepan (Figure 8), a standard
ligand to this channel (Cope et al., 2005). MD simulation
(Figures 7A–F, 8) showed complex behavior after 20 ns
MMPBSA. The RMSD of 2YOE-valerenic acid complex was
0.5 Å, while in the complex 2YOE-apigenin was 0.6 Å. In
the analysis of structural stability of both Valeriana ligands,
valerenic acid presented an RMSD of 0.07 Å and apigenin, 1.3
Å. Furthermore, we observed constant fluctuations in GABAA,
between 0.07 Å and 0.13 Å, when the receptor is complexed
with apigenin. On the other hand, GABAA presentedmore stable
when complexed with valerenic acid, ranging from 0.07 to 0.11
Å of fluctuation. Additionally, when we verified the number of
hydrogen bonds, valerenic acid seemed more stable, changing
from 2 to 3 hydrogen bonds, while apigenin presented just one
hydrogen bond for all simulation time. As expected, Valerian
compounds complexes in the same GABAA active site with
Flurazepan, thus confirming our hypothesis (Figure 8).
Valerian Compounds and SUR1
Regarding the docking results (Table 3), as well as the 2D
map interactions (Figure 9D), we selected hesperidin as the
molecule with the best capacity to interact with SUR1. Figure 9A
shows the RMSD fluctuations of the complex SUR1-hesperidin.
As observed, the interaction was stable from the first steps of
simulation until the end of the 20 ns. The RMSD of the ligand
was almost invariable (Figure 9B), as well as the complex. From
the beginning of the simulation up to 10 ns, the number of
hydrogen bonds between SUR-hesperidin varied from 5 to 1 and
after it reached three interactions at the end of the simulation
(Figure 9C). The final binding free energy value at 20 ns was
−119.771 KJ/mol (±4.841). These results indicated that SUR1
and hesperidin formed a strong and stable interaction from the
beginning until the end of 20 ns of simulation. This can be
explained because the SUR1 active site and hesperidin share most
of hydrophobic features. Indeed, SUR1 may interact with Kir6.2,
a transcript of ABBC8, thus forming a complete functional
channel.
DISCUSSION
PD includes multiscale dysfunctions associated to severe loss of
nigrostriatal neurons mainly associated to oxidative stress attack,
and abnormal concentration of amyloid plaques derived from the
oxidation of substances such as dopamine and high amount of
SNCA (Gaiteri et al., 2014). It is recognized that mutations in
diferents genes such as SNCA, parkin (PRKN), LRRK2, PTEN-
induced putative kinase 1 (PINK1) are involved in some sporadic
forms of the PD (Wood-Kaczmar et al., 2006; Gaiteri et al., 2014).
As reported by our analysis, only SNCA and TH are shown as a
hub gene related to our previous experiments in de Oliveria et al.
(2009) (Figure 2B). In spite of strong evidences, the precisely
physiological function of SNCA and its interaction with TH on
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FIGURE 7 | Twenty nanoseconds Molecular Dynamics (MD) Molecular Mechanic Poison/Boltzman Surface Area (MMPBSA) for complexes between
GABAA with apigenin and valerenic acid. (A) Root mean square deviation (RMSD) fluctuations for GABAA-Apigenin complex; (B) RMSD fluctuations for valerenic
acid; (C) Apigenin RMSD variation; (D) valerenic acid RMSD variations; (E) hydrogen bonds fluctuations for apigenin inside GABAA active site; (F) hydrogen bonds
fluctuations for valerenic acid inside GABAA active site.
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PD do not remain clear. However, some studies have shown
that SNCA is differentially expressed in cell compartments.
It has a high expression in inner mitochondrial membrane
when compared to the cell cytoplasm. In mammalian brain,
SNCA is predominantly expressed in hippocampal formation
and striatum, with many evidences showing that the protein
plays a role in several neurodegenerative disease (Dodson and
Guo, 2007). A single mutation (SNP) of the SNCA gene can
also lead to a general form of PD, resulting in the accumulation
of Lewy bodies within the surviving cells (Mata et al., 2006).
This reduction in solubility of synuclein modifies the action
of the enzyme TH, resulting in an increased concentration of
dopamine and cytoplasmic ROS generated from its derivatives
in oxidation form (Qi et al., 2014). As observed in Table 1,
SNCA does not seem to be the substrate of the main components
of Valeriana oficcinalis. In contrast, TH and dopamine may be
the key for the preferential susceptibility of death in neurons
containing dopamine in PD. A great body of in vitro and in vivo
evidences, especially those associated with pesticide rotenone and
inhibition of Cx-I, have been very useful (Cabeza-Arvelaiz and
Schiestl, 2012; Giordano et al., 2012). Nevertheless, if we consider
that rotenone causes mitochondrial Cx-I inhibition on entirely
brain regions, and not only on SN cells, these unspecified brain
distribution and preference for neurons containing dopamine
may suggest that inhibition of Cx-I should be a secondary route
of toxicity. Therefore, there must be something intrinsically
related to dopamine metabolism, such as ATP depletion,
dopamine overproduction and imbalance of NAD+/NADH,
which are capable to induce selective death of dopaminergic
neurons (Cabeza-Arvelaiz and Schiestl, 2012). Furthermore, our
experiments with molecular docking between rotenone and Cx-I
revealed a lower affinity energy of−7.8 Kcal/mol when compared
to −10 Kcal/mol (Supplementary Table 1) exhibited by the
complex with NADH, putting forward a new consideration about
rotenone and neuronal cell death.
Reduction on membrane mitochondrial potential (MMTP)
decreases ATP/ADP concentrations, promoting Ca++ imbalance
and increasing of ROS production as a consequence (Sai
et al., 2008). Moreover, rotenone leads to upregulation and
aggregation of SNCA and APP conversion into the form
beta amiloid, which is related to endoplasmic reticulum (ER)
stress by SNCA oligomer accumulation. These findings are in
agreement with our analysis of centrality using microarray data
(Figure 2B).
Impairments on mitochondrial respiration play several
important functions in neuronal death on SN in PD, a cerebral
TABLE 3 | Affinity energies for docking calculations between Kir and
SUR1 with Valerian compounds.
Target Valerian compound RMSD Affinity energy (Kcal/Mol)
SUR Hesperidin 0 −6.3
Linarin 0 −5.9
Apigenin 0 −5.2
Valerenic acid 0 −4.5
Kir Apigenin 0 −6.5
Valerenic acid 0 −5.5
FIGURE 8 | GABAA receptor docked with Flurazepan and Valerian
compounds. Apigenin (yellow) and valerenic acid docked in the same site of
Flurazepan (red).
region with dense expression of K-ATP channels (Henchcliffe
and Beal, 2008; Perier and Vila, 2012).
The genes ABCC8 (SUR1), an ATP Bind Cassette
subfamily, are associated to couple cellular energetic process
to transmembrane potential by controlling the sensitivity
of type ATP-inward-rectifier potassium channels, such that
coded by kcnj4 and Kcnj11 (Liss et al., 2005). SN plays a
key role in protecting neurons from seizures by preventing
hyperexcitation under asphyxia or ATP depletion due to its
capacity to release GABA in neuronal cell terminal. In this
area, GABAergic pre-synaptic neurons have predominantly
potassium ATP (KATP) channels that modulate the release
of this neurotransmitter. An increase in ATP/ADP rates
(high metabolic glucose consumption) closes the channel
leading to cell depolarization by Ca++ influx (Liss et al.,
2005; Sun and Feng, 2013). Under stress circumstances,
such that induced by rotenone, the reduction of ATP/ADP
prevents SN to release GABA, and, consequently, low levels
of GABA may lead to cell damage as well as an increase
in dopamine release (Amoroso et al., 1990; Sun and Feng,
2013).
According to our docking analysis (Figure 6), valerenic acid
binds to SUR1 active site. This ligand accepts one hydrogen by
its carboxyl group from ASN 828 and forms other electrostatic
and Van der Waals interactions with other eight amino acids.
These interactions are weak, when compared to the response of
valerenic acid to GABAA receptors (Yuan et al., 2004; Khom
et al., 2007, 2010; Trauner et al., 2008). In such situation,
valerenic acid seems to have a secondary effect in SUR1
(Figure 6).
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FIGURE 9 | MMPBSA simulation results for the complex SUR1 with hesperidin and 2D interaction map. (A) RMSD fluctuations for SUR1-Hesperidin
complex; (B) RMSD fluctuations for hesperidin; (C) hydrogen bonds fluctuations for hesperidin inside SUR1 active site; (D) 2D interaction map for hesperidin inside
SUR1 active pocket.
At the same way, docking between apigenin and SUR1 shows
ARG 836 acting as a cation and forming two Pi interactions
with the ligand. Other interactions are mainly electrostatic and
the stereochemical effect is similar to valerenic acid, which
explains its affinity with GABAA receptors (Avallone et al., 2000),
reducing dopamine toxicity overproduction and preventing
dopamine release from SN’s nerve cells, a pivotal area in
development of PD.
Another possible neuroprotective effect exerted by Valerian
in PD model reported by de Oliveria et al. (2009) appears
to be accomplished by its flavones hesperidin and linarin on
KATP channel sensor (SUR1). Complex hesperidin-SUR1
shows a strong interaction in the active site. ARG 836 and
SER 830 formed Pi and Sigma interactions, respectively.
The ligand accepted seven hydrogen interactions from
GLN 833, ASN 828, LEU 829, GLY 831, ALA 858, and its
stereochemistry seemed to make a more stabilized docking,
in comparison to valerenic acid and apigenin. Moreover,
hesperidin activity is described as reducing oxidative stress
(Tirkey et al., 2005) and acting in MAPK pathway (Kim
et al., 2011). At the same way of hesperidin, linarin fitted
strongly to SUR1 receptor. The ligand mainly interacted
to SER 857, accepting one hydrogen bond and donating
two. Other interactions were electrostatic and Van der
Waals.
As previously described, hesperidin and linarin are two of the
main constituent of Valeriana’s extract exhibiting a high affinity
to KATP channel, which are related to the control of Ca++
concentration and release of GABA in synaptic nerve terminal,
mainly on cells of SN (Henchcliffe and Beal, 2008; Perier and
Vila, 2012). Due to the blockage of KATP channel by binding to
SUR1 (internal subunit associated to Kir6.2), flavones ofValerian
should revert the membrane transient toward the positive status.
At the same way, voltage sensitive Ca++ inward opens to
restore the balance between ATP depletion. Theses flavones
in such situation could resemble a ATP signaling, activating
Kir6.2 to restore MMTP and thus preventing apoptosis in SN
neuronal cell containing dopamine, a remarkable consequence
in PD.
Our report brings a new approach using hesperidin and
linarin relating to alleviating the effects of oxidative stress in PD.
Some authors described linarin activity as sedative and sleep-
enhancer (Fernández et al., 2004), but it was not related to any
specific receptor. Additionally, linarin was described as a selective
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inhibitor of acetilcholinesterase (Oinonen et al., 2006). Thus, this
is the first study describing themechanism of interaction between
SUR1 and linarin as a probable inhibitor ligand. Finally, in this
work we suggest that hesperidin and linarin have a synergic
activity in Valerian’s extracts, thus corroborating our previous
experimental data in the in vitro PD model (de Oliveria et al.,
2009).
CONCLUSION
Despite the complexity relating to evaluating a plant extract
and its constituent interactions, we performed several theoretical
analysis trying to figure out the key role of the neuroprotective
effect exerted by the extract of Valeriana officinalis. Its most
remarkable effect is associated to anxiety and sleep modulation
mediated by valerenic acid and the flavon apigenin by binding
as agonists to GABAA receptors in brainstem (Trauner et al.,
2008). Similarly in previous studies, our data suggest that there
are, at least, two main pathways associated to pharmacological
effect of Valerian’s neuroprotection in PD model (Riedel
et al., 1982). It appears to be carried out by a GABAergic
activity, reducing neuronal hyperactivity and dopamine release
during oxidative stress, a situation associated to ATP/ADP
mitochondrial balance.
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